Docoh
Loading...

77 results

Filter options loading...
Top filers
Top filing types
Recent filing years
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
herein contain certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A … by reference herein contain certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A
8-K
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
or assets is the subject which are not described in the Prospectus, including ordinary routine litigation incidental to the business, could not reasonably … is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) have not received notice that any governmental authority
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
, prosecuting, maintaining, expanding, defending, and enforcing patent claims, including litigation costs and the outcome of such litigation; the extent
S-3
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Shelf registration
4:02pm
the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. All statements … . These provisions also may reduce the likelihood of derivative litigation against our directors and officers, even though such an action, if successful, might
8-K
EX-10.1
b7dat8n3oxrbdmj7
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-99.1
q26oizkziw4kq
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
10-Q
35zryy p184jypo
13 May 21
Quarterly report
4:30pm
DEF 14A
7w8z xw9nzy7oysg4wm
22 Apr 21
Definitive proxy
2:00pm
424B3
uo5eiu3 v419
12 Apr 21
Prospectus supplement
1:44pm
S-3
lc1umk4233ua
1 Apr 21
Shelf registration
8:00pm
10-K
qjvpmjfvhmf6
24 Mar 21
Annual report
8:00pm
8-K
EX-10.1
vgdvyyj4na2jftkfhf71
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-1.1
wipywg
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
tmwoc vbdh709v
5 Oct 20
Prospectus supplement with pricing info
4:16pm
S-1/A
97vlnsl03n f7gzrr0t
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
ztobg6f r9rfo1hqdoy
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-2.1
rvzjl56
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-1.1
8q27qb6p7 hlab8b9qt
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-10.5
5u1f v2ar
16 Sep 20
IPO registration (amended)
8:00pm